Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Active, not recruiting Phase 2 Interventional

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

NCT07012005
View directory record Official record
Conditions
Renal Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Elemental Diet and Gut Microbiome

NCT05978973
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Elemental Diet
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

NCT00602342
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Early Phase 1 Interventional

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

NCT03400501
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 27, 2026, 7:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Temporal Interference for Thalamocortical Activity and Network Modulation

NCT07219719
View directory record Official record
Conditions
Healthy Participants
Interventions
Temporal Interference Transcranial electrical stimulation (TI-TES), Sham stimulation
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

NCT03543137
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine Prototype Mini lozenge, Nicorette Mini Lozenge
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment for the Treatment of Keloid Scar

NCT04016610
View directory record Official record
Conditions
Keloid Scar
Interventions
Soliton's Acoustic Scar Reduction (SAR)
Device
Lead sponsor
Soliton
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time-restricted Eating Acceptability, Efficacy and Safety in Obesity

NCT06695988
View directory record Official record
Conditions
Time Restricted Eating, Obesity
Interventions
Time Restricted Eating
Behavioral
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Oxford, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy

NCT04520256
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Online Behavioral Weight Loss Program, Virtual Reality for Behavioral Weight Loss Skills Training, Tailored Interactive Video Feedback, Tailored Intervention for Structured Physical Activity, Skills Training for Dysregulated Eating, Platform for Social Support & Friendly Competition
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions

NCT00618202
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Balsalazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

NCT03960502
View directory record Official record
Conditions
Healthy Male Participants
Interventions
AG-881, [13C315N3]AG-881
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 27, 2026, 7:32 AM EDT
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

NCT04877522
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
7 Years to 100 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

NCT02472561
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Fitbit Physical Activity Monitor, mHealth Glucometer, mHealth Blood Pressure
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

NCT00117637
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006), Interferon
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Verapamil ER

NCT00983242
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Verapamil HCl ER
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 27, 2026, 7:32 AM EDT
Not yet recruiting Not applicable Interventional

Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation

NCT01952873
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Stent Occlusion
Interventions
Prolonged inflation, Rapid inflation
Other
Lead sponsor
Central Arkansas Veterans Healthcare System
Federal
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 7:32 AM EDT
Terminated Not applicable Interventional

RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease

NCT03365531
View directory record Official record
Conditions
NAFLD, Obesity, Diabetes Mellitus, Type 2
Interventions
Alternate Daily Fasting (ADF), Caloric Restriction (CR)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Perceptions of and Reactions to Ultra-Processed Menu Label Designs

NCT07214805
View directory record Official record
Conditions
Food Choices
Interventions
Ultra-Processed, Red, Icon-plus-text Labels, Contains Food Additives, Red, Icon-plus-text Labels, Warning Ultra-Processed, Red, Icon-plus-text Labels, Warning UPF, Red, Icon-plus-text Labels, Ultra-Processed, Yellow, Icon-plus-text Labels, Contains Food Additives, Yellow, Icon-plus-text Labels, Warning Ultra-Processed, Yellow, Icon-plus-text Labels, Warning UPF, Yellow, Icon-plus-text Labels, Ultra-Processed, Red, Text-only Labels, Contains Food Additives, Red, Text-only Labels, Warning Ultra-Processed, Red, Text-only Labels, Warning UPF, Red, Text-only Labels, Ultra-Processed, Yellow, Text-only Labels, Contains Food Additives, Yellow, Text-only Labels, Warning Ultra-Processed, Yellow, Text-only Labels, Warning UPF, Yellow, Text-only Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
14,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Four Arm Food Effect Study of Fenofibric Acid Tablets

NCT00960856
View directory record Official record
Conditions
Healthy
Interventions
Fenofibric Acid 105 mg Tablet
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2009 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg

NCT00648531
View directory record Official record
Conditions
Healthy
Interventions
Balsalazide Disodium Capsules 750 mg, Colazal® Capsules 750 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 2 Interventional

Safety Study of Tecadenoson to Treat Atrial Fibrillation

NCT00713401
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Tecadenoson, Esmolol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 27, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

NCT01170975
View directory record Official record
Conditions
Solid Tumors
Interventions
Tesetaxel 10 mg with and then without food, Tesetaxel 10 mg without and then with food
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 27, 2026, 7:32 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

NCT07856706
View directory record Official record
Conditions
Healthy Subjects
Interventions
ABBV-7828, Placebo for ABBV-7828
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 7:32 AM EDT